Immuno-Oncology Alliances Command Big Deal Premiums
les Nouvelles - Journal of the Licensing Executives Society, Volume LIV No. 1, March 2019
5 Pages Posted: 24 Mar 2019
Date Written: January 16, 2019
Everyone knows that immune-oncology (IO) is the hottest ticket in biopharma alliances. With almost 100 announced deals involving PD-1, and more than half as many with PD-L1, it seems that everyone is jumping onto the IO dancefloor. However, as with all things alliance-related, the devil is in the details. What IO molecular target(s) should one bring to the dance? CD20, HER1 or HER2, TNF-alpha, CTLA4… and the list goes on. And when is the optimal time to seek and strike a deal: preclinical data, Phase I safety data, Phase II clinical proof of concept, or Phase III pivotal trials as a monotherapy? In other words, with such a crowded dancefloor, when is the best time to join the IO dance?
Keywords: Immuno-Oncology, IO Dancefloor, CD20, HER1, HER2, TNF-Alpha, CTLA4, Monotherapy
Suggested Citation: Suggested Citation